2026-04-18T01:28:27Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/118502025-10-24T10:32:40Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Nuñez-Conde, A.
author
Castella Fierro, Eva
author
Aceituno, Laia
author
Escolà-Vergé, Laura
author
Pigrau, Carlos
author
Len, Oscar
author
Falcó, Vicenç
author
VIÑADO, BELEN
author
Serra-Pladevall, Judit
2025-10-24T10:32:40Z
2025-10-24T10:32:40Z
2024-08-21T07:38:26Z2024-08-21T07:38:26Z2024-06-10
http://hdl.handle.net/11351/11850
Acute focal pyelonephritis; Quinolones; Urinary tract infectionsPielonefritis focal aguda; Quinolones; Infeccions del tracte urinariPielonefritis focal aguda; Quinolonas; Infecciones del tracto urinarioBackground
Evidence regarding the best antibiotic regimen and the route of administration to treat acute focal bacterial nephritis (AFBN) is scarce. The aim of the present study was to compare the effectiveness of intravenous (IV) β-lactam antibiotics versus oral quinolones.
Methods
This is a retrospective single centre study of patients diagnosed with AFBN between January 2017 and December 2018 in Hospital Universitari Vall d’Hebron, Barcelona (Spain). Patients were identified from the diagnostic codifications database. Patients treated with oral quinolones were compared with those treated with IV β-lactam antibiotics. Therapeutic failure was defined as death, relapse, or evolution to abscess within the first 30 days.
Results
A total of 264 patients fulfilled the inclusion criteria. Of those, 103 patients (39%) received oral ciprofloxacin, and 70 (26.5%) IV β-lactam. The most common isolated microorganism was Escherichia coli (149, 73.8%) followed by Klebsiella pneumoniae (26, 12.9%). Mean duration of treatment was 21.3 days (SD 7.9). There were no statistical differences regarding therapeutic failure between oral quinolones and IV β-lactam treatment (6.6% vs. 8.7%, p = 0.6). Out of the 66 patients treated with intravenous antibiotics, 4 (6.1%) experienced an episode of phlebitis and 1 patient (1.5%) an episode of catheter-related bacteraemia.
Conclusions
When susceptible, treatment of AFBN with oral quinolones is as effective as IV β-lactam treatment with fewer adverse events.Open Access Funding provided by Universitat Autonoma de Barcelona.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Avaluació de resultats (Assistència sanitària)
Malalties bacterianes - Tractament
Medicaments antibacterians - Ús terapèutic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents
Other subheadings::Other subheadings::/therapeutic use
DISEASES::Bacterial Infections and Mycoses::Bacterial Infections
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos
Otros calificadores::Otros calificadores::/uso terapéutico
ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
Oral quinolones versus intravenous β-lactam for the treatment of acute focal bacterial nephritis: a retrospective cohort study
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion